Clinical trial
Belinostat in Treating Patients With Myelodysplastic Syndromes
NCT00357162 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00357162 |
|---|---|
| Title | Belinostat in Treating Patients With Myelodysplastic Syndromes |
| Official title | Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | belinostat |
| Enrollment | 21 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jul 27, 2006 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: